Your browser doesn't support javascript.
loading
The influence of obesity-related factors in the etiology of renal cell carcinoma-A mendelian randomization study.
Johansson, Mattias; Carreras-Torres, Robert; Scelo, Ghislaine; Purdue, Mark P; Mariosa, Daniela; Muller, David C; Timpson, Nicolas J; Haycock, Philip C; Brown, Kevin M; Wang, Zhaoming; Ye, Yuanqing; Hofmann, Jonathan N; Foll, Matthieu; Gaborieau, Valerie; Machiela, Mitchell J; Colli, Leandro M; Li, Peng; Garnier, Jean-Guillaume; Blanche, Helene; Boland, Anne; Burdette, Laurie; Prokhortchouk, Egor; Skryabin, Konstantin G; Yeager, Meredith; Radojevic-Skodric, Sanja; Ognjanovic, Simona; Foretova, Lenka; Holcatova, Ivana; Janout, Vladimir; Mates, Dana; Mukeriya, Anush; Rascu, Stefan; Zaridze, David; Bencko, Vladimir; Cybulski, Cezary; Fabianova, Eleonora; Jinga, Viorel; Lissowska, Jolanta; Lubinski, Jan; Navratilova, Marie; Rudnai, Peter; Benhamou, Simone; Cancel-Tassin, Geraldine; Cussenot, Olivier; Weiderpass, Elisabete; Ljungberg, Börje; Tumkur Sitaram, Raviprakash; Häggström, Christel; Bruinsma, Fiona; Jordan, Susan J.
Afiliação
  • Johansson M; International Agency for Research on Cancer (IARC), Lyon, France.
  • Carreras-Torres R; International Agency for Research on Cancer (IARC), Lyon, France.
  • Scelo G; International Agency for Research on Cancer (IARC), Lyon, France.
  • Purdue MP; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, Maryland, United States of America.
  • Mariosa D; International Agency for Research on Cancer (IARC), Lyon, France.
  • Muller DC; Imperial College, London, United Kingdom.
  • Timpson NJ; MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom.
  • Haycock PC; MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom.
  • Brown KM; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, Maryland, United States of America.
  • Wang Z; St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
  • Ye Y; Department of Epidemiology, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
  • Hofmann JN; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, Maryland, United States of America.
  • Foll M; International Agency for Research on Cancer (IARC), Lyon, France.
  • Gaborieau V; International Agency for Research on Cancer (IARC), Lyon, France.
  • Machiela MJ; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, Maryland, United States of America.
  • Colli LM; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, Maryland, United States of America.
  • Li P; International Agency for Research on Cancer (IARC), Lyon, France.
  • Garnier JG; Max Planck Institute for Demographic Research, Rostock, Germany.
  • Blanche H; Centre National de Genotypage, Institut de Genomique, Centre de l'Energie Atomique et aux Energies Alternatives, Evry, France.
  • Boland A; Fondation Jean Dausset - Centre d'Etude du Polymorphisme Humain, Paris, France.
  • Burdette L; Fondation Jean Dausset - Centre d'Etude du Polymorphisme Humain, Paris, France.
  • Prokhortchouk E; Centre National de Genotypage, Institut de Genomique, Centre de l'Energie Atomique et aux Energies Alternatives, Evry, France.
  • Skryabin KG; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, Maryland, United States of America.
  • Yeager M; Federal Research Centre "Fundamentals of Biotechnology" of the Russian Academy of Sciences, Moscow, Russian Federation.
  • Radojevic-Skodric S; Federal Research Centre "Fundamentals of Biotechnology" of the Russian Academy of Sciences, Moscow, Russian Federation.
  • Ognjanovic S; Kurchatov Scientific Center, Moscow, Russian Federation.
  • Foretova L; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, Maryland, United States of America.
  • Holcatova I; Institute of Pathology, Medical School of Belgrade, Belgrade, Serbia.
  • Janout V; Clinic of Urology, Clinical Center of Serbia, Belgrade, Serbia.
  • Mates D; Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota, United States of America.
  • Mukeriya A; International Organization for Cancer Prevention and Research (IOCPR), Belgrade, Serbia.
  • Rascu S; Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
  • Zaridze D; Institute of Public Health and Preventive Medicine, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Bencko V; Department of Preventive Medicine, Faculty of Medicine, Palacky University, Olomouc, Czech Republic.
  • Cybulski C; National Institute of Public Health, Bucharest, Romania.
  • Fabianova E; Russian N.N. Blokhin Cancer Research Centre, Moscow, Russian Federation.
  • Jinga V; Carol Davila University of Medicine and Pharmacy, Th. Burghele Hospital, Bucharest, Romania.
  • Lissowska J; Russian N.N. Blokhin Cancer Research Centre, Moscow, Russian Federation.
  • Lubinski J; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Navratilova M; International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
  • Rudnai P; Regional Authority of Public Health in Banska Bystrica, Banska Bystrica, Slovakia.
  • Benhamou S; Carol Davila University of Medicine and Pharmacy, Th. Burghele Hospital, Bucharest, Romania.
  • Cancel-Tassin G; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland.
  • Cussenot O; International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
  • Weiderpass E; Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
  • Ljungberg B; National Public Health Center, National Directorate of Environmental Health, Budapest, Hungary.
  • Tumkur Sitaram R; INSERM U946, Paris, France.
  • Häggström C; CNRS UMR8200, Institute Gustave Roussy, Villejuif, France.
  • Bruinsma F; CeRePP, Paris, France.
  • Jordan SJ; UPMC Univ Paris 06, GRC n°5, Institut Universitaire de Cancérologie, Paris, France.
PLoS Med ; 16(1): e1002724, 2019 01.
Article em En | MEDLINE | ID: mdl-30605491
BACKGROUND: Several obesity-related factors have been associated with renal cell carcinoma (RCC), but it is unclear which individual factors directly influence risk. We addressed this question using genetic markers as proxies for putative risk factors and evaluated their relation to RCC risk in a mendelian randomization (MR) framework. This methodology limits bias due to confounding and is not affected by reverse causation. METHODS AND FINDINGS: Genetic markers associated with obesity measures, blood pressure, lipids, type 2 diabetes, insulin, and glucose were initially identified as instrumental variables, and their association with RCC risk was subsequently evaluated in a genome-wide association study (GWAS) of 10,784 RCC patients and 20,406 control participants in a 2-sample MR framework. The effect on RCC risk was estimated by calculating odds ratios (ORSD) for a standard deviation (SD) increment in each risk factor. The MR analysis indicated that higher body mass index increases the risk of RCC (ORSD: 1.56, 95% confidence interval [CI] 1.44-1.70), with comparable results for waist-to-hip ratio (ORSD: 1.63, 95% CI 1.40-1.90) and body fat percentage (ORSD: 1.66, 95% CI 1.44-1.90). This analysis further indicated that higher fasting insulin (ORSD: 1.82, 95% CI 1.30-2.55) and diastolic blood pressure (DBP; ORSD: 1.28, 95% CI 1.11-1.47), but not systolic blood pressure (ORSD: 0.98, 95% CI 0.84-1.14), increase the risk for RCC. No association with RCC risk was seen for lipids, overall type 2 diabetes, or fasting glucose. CONCLUSIONS: This study provides novel evidence for an etiological role of insulin in RCC, as well as confirmatory evidence that obesity and DBP influence RCC risk.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais / Obesidade Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: PLoS Med Assunto da revista: MEDICINA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais / Obesidade Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: PLoS Med Assunto da revista: MEDICINA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: França